Literature DB >> 12663814

A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.

Martin Markowitz1, Michael Louie, Arlene Hurley, Eugene Sun, Michele Di Mascio, Alan S Perelson, David D Ho.   

Abstract

Mathematical models provide an understanding of in vivo replication kinetics of human immunodeficiency virus type 1 (HIV-1). With a novel intervention designed for increased potency, we have more accurately deduced the half-lives of virus-producing CD4(+) T cells, 0.7 day, and the generation time of HIV-1 in vivo, approximately 2 days, confirming the dynamic nature of HIV-1 replication.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12663814      PMCID： PMC152136          DOI： 10.1128/jvi.77.8.5037-5038.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  7 in total

1.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

2.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

3.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

4.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  Determining the relative efficacy of highly active antiretroviral therapy.

Authors:  Michael Louie; Christine Hogan; Michele Di Mascio; Arlene Hurley; Viviana Simon; James Rooney; Nancy Ruiz; Scott Brun; Eugene Sun; Alan S Perelson; David D Ho; Martin Markowitz
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

Review 6.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

7.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962
  7 in total
  182 in total

1.  Persistence and emergence of X4 virus in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson
Journal:  Math Biosci Eng       Date:  2011-04       Impact factor: 2.080

2.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Authors:  Jeffrey M Jacobson; Jacob P Lalezari; Melanie A Thompson; Carl J Fichtenbaum; Michael S Saag; Barry S Zingman; Paul D'Ambrosio; Nancy Stambler; Yakov Rotshteyn; Andre J Marozsan; Paul J Maddon; Stephen A Morris; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

4.  SPMM: estimating infection duration of multivariant HIV-1 infections.

Authors:  Tanzy M T Love; Sung Yong Park; Elena E Giorgi; Wendy J Mack; Alan S Perelson; Ha Youn Lee
Journal:  Bioinformatics       Date:  2015-12-31       Impact factor: 6.937

5.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

6.  Selection on the human immunodeficiency virus type 1 proteome following primary infection.

Authors:  Yi Liu; John McNevin; Jianhong Cao; Hong Zhao; Indira Genowati; Kim Wong; Sherry McLaughlin; Matthew D McSweyn; Kurt Diem; Claire E Stevens; Janine Maenza; Hongxia He; David C Nickle; Daniel Shriner; Sarah E Holte; Ann C Collier; Lawrence Corey; M Juliana McElrath; James I Mullins
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy.

Authors:  Eleonor Brandin; Rigmor Thorstensson; Sebastian Bonhoeffer; Jan Albert
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

8.  Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.

Authors:  Hulin Wu; Yangxin Huang; Edward P Acosta; Jeong-Gun Park; Song Yu; Susan L Rosenkranz; Daniel R Kuritzkes; Joseph J Eron; Alan S Perelson; John G Gerber
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-01       Impact factor: 2.745

9.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.

Authors:  J Michael Kilby; Ha Youn Lee; J Darren Hazelwood; Anju Bansal; R Patterson Bucy; Michael S Saag; George M Shaw; Edward P Acosta; Victoria A Johnson; Alan S Perelson; Paul A Goepfert
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.